company background image
PHMM.F logo

Pharma Mar OTCPK:PHMM.F Stock Report

Last Price

US$29.29

Market Cap

US$545.1m

7D

-3.6%

1Y

-38.6%

Updated

27 Mar, 2024

Data

Company Financials +

PHMM.F Stock Overview

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally.

PHMM.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance1/6
Financial Health4/6
Dividends1/6

Pharma Mar, S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pharma Mar
Historical stock prices
Current Share Price€29.29
52 Week High€47.11
52 Week Low€29.29
Beta-0.018
1 Month Change-12.96%
3 Month Changen/a
1 Year Change-38.60%
3 Year Change-73.94%
5 Year Change1,536.31%
Change since IPO1,201.78%

Recent News & Updates

Recent updates

Shareholder Returns

PHMM.FUS BiotechsUS Market
7D-3.6%0.9%0.4%
1Y-38.6%10.3%28.8%

Return vs Industry: PHMM.F underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: PHMM.F underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is PHMM.F's price volatile compared to industry and market?
PHMM.F volatility
PHMM.F Average Weekly Movementn/a
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: PHMM.F's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine PHMM.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1986509Jose Fernandez Sousa-Farohttps://www.pharmamar.com

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer.

Pharma Mar, S.A. Fundamentals Summary

How do Pharma Mar's earnings and revenue compare to its market cap?
PHMM.F fundamental statistics
Market capUS$545.11m
Earnings (TTM)US$1.23m
Revenue (TTM)US$171.12m

436.6x

P/E Ratio

3.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHMM.F income statement (TTM)
Revenue€158.15m
Cost of Revenue€9.61m
Gross Profit€148.54m
Other Expenses€147.40m
Earnings€1.14m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.064
Gross Margin93.92%
Net Profit Margin0.72%
Debt/Equity Ratio20.6%

How did PHMM.F perform over the long term?

See historical performance and comparison

Dividends

2.3%

Current Dividend Yield

1,023%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.